Clinical Trial

Intravenous Infusion of Human Mesenchymal Stem Cells (HMM910 ) in Postmenopausal Women With Osteoporosis at High Risk of Fracture

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated February 10, 2026 (before its estimated March 6, 2026 completion). Its status may not reflect the trial's current state.
Summary
The primary objective of this study is to evaluate the safety and tolerability of human umbilical cord-derived mesenchymal stem cells for injection (HMM910 ) in postmenopausal women with osteoporosis who are at high risk of fracture.
Protocol Amendment History 1 change
notable Sponsor changed: Help Therapeutics -> HELP Therapeutics Co., Ltd. 2026-04-05
Trial Details
NCT Number NCT06949137
Lead Sponsor Help Therapeutics
Collaborators: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Conditions Osteoporosis in Post-menopausal Women, Osteoporosis
Enrollment 9 participants
Start Date 2025-06-20
Primary Completion 2026-03-06 (estimated)
Study Completion 2026-09-06 (estimated)
Updated on ClinicalTrials.gov 2026-02-10